Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 83, Issue 4, Pages 909-922Publisher
WILEY
DOI: 10.1111/bcp.13161
Keywords
antidepressive agents; cohort studies; congenital anomalies; meta-analysis; pregnancy; sertraline
Categories
Funding
- China National Health and Family Planning Commission [201402006]
- Obstetric Diseases Translational Medicine Research Center Project of Liaoning Province [2014225007]
- Natural Science Foundation of China [81402130, 81602918]
- Doctoral Start-up Foundation of Liaoning Province [201501007, 20141045]
- Fok Ying Tung Education Foundation [151039]
- Campus Research Fund of China Medical University [YQ20160004]
- Fogarty International Clinical Research Scholars and Fellows Support Center at the Vanderbilt Institute for Global Health - Fogarty International Center, NIH [D43 TW008313]
Ask authors/readers for more resources
AimTo perform a meta-analysis of available cohort studies on the association between sertraline use by pregnant women in the first trimester and the findings of congenital anomalies in infants. MethodsA comprehensive search of articles published from the index date up to 31(st) December 2015 investigating the aforementioned associations was conducted on PubMed and Web of Science. Mesh headings used included the terms serotonin reuptake inhibitor, sertraline, congenital anomalies and obstetrical outcome. ResultsTwelve cohort studies that involved 6 468 241 pregnant women were identified. We summarized odds ratios (ORs) and 95% confidence intervals (CIs) of congenital anomalies using the random-effects model. Pregnant women who used sertraline in the first trimester had a statistically significant increased risk of infant cardiovascular-related malformations (OR=1.36; 95% CI=1.06-1.74; I-2=64.4%; n=12) as well as atrial and/or ventricular septal defects (OR=1.36, 95% CI=1.06-1.76; I-2=62.2%; n=8). Additionally, positive but nonsignificant associations between sertraline use and congenital anomalies of the nervous system (OR=1.39; 95% CI=0.83-2.32; I-2=0%; n=5), digestive system (OR=1.23; 95% CI=0.76-1.98; I-2=0%; n=5), eye, ear, face and neck (OR=1.08; 95% CI=0.33-3.55; I-2=32.1%; n=3), urogenital system (OR=1.03; 95% CI=0.73-1.46; I-2=0%; n=5), and musculoskeletal system (OR=0.97; 95% CI=0.69-1.36; I-2=0%; n=5) were observed. ConclusionThis meta-analysis suggested that the use of sertraline use by pregnant women in the first trimester had an increased risk of cardiovascular-related malformations as well as atrial and/or ventricular septal defects in infants. Meanwhile, nonsignificant associations between sertraline use and other congenital anomalies were found. More cohort studies are warranted to provide detailed results of other congenital anomalies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available